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Patients with type 2 diabetes (T2D) display an increased risk for premature cardiovascular disease and death.1 
Several factors may contribute to this, including hypergly-
cemia, dyslipidemia, and inflammation.1 Levels of plasma 
low-density lipoprotein (LDL) cholesterol are usually not 
markedly elevated in T2D patients; instead they often pres-
ent with reduced high-density lipoprotein (HDL) cholesterol 
levels. Importantly, lipid-lowering therapy is of clear benefit 
for T2D patients.2
We recently investigated the hypothesis that T2D patients 
might have increased levels of LDL in interstitial fluid (IF) 
because of an enhanced leakage over the vascular wall.3 
However, we unexpectedly observed the opposite, ie, that 
T2D patients have less apolipoprotein B (apoB)–containing 
lipoproteins (very low-density lipoprotein and LDL) in IF rel-
ative to serum compared with healthy controls.3 These results 
indicated an increased accumulation or catabolism of apoB-
containing particles in the interstitial compartment in T2D. 
In contrast, the level of HDL cholesterol in IF did not differ 
between T2D patients and healthy controls.3
HDL metabolism plays an important role for the devel-
opment of atherosclerosis, and the inverse relationship 
between HDL cholesterol levels and cardiovascular disease 
is well established.4 However, attempts to pharmacologically 
increase plasma HDL-cholesterol failed to show clinical ben-
efit.5–7 It has recently become evident that the functional prop-
erties of HDL particles are important for their atheroprotective 
function, more than the circulating levels per se.8 One major 
function of HDL is its key role in reverse cholesterol trans-
port, ie, transport of cholesterol from peripheral tissues to the 
liver for subsequent biliary and fecal excretion. In this pro-
cess, the capacity of the HDL particle to promote cholesterol 
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Objective—Patients with type 2 diabetes mellitus (T2D) have an increased risk of cardiovascular disease, the mechanism of 
which is incompletely understood. Their high-density lipoprotein (HDL) particles in plasma have been reported to have 
impaired cholesterol efflux capacity. However, the efflux capacity of HDL from interstitial fluid (IF), the starting point 
for reverse cholesterol transport, has not been studied. We here investigated the cholesterol efflux capacity of HDL from 
IF and plasma from T2D patients and healthy controls.
Approach and Results—HDL was isolated from IF and peripheral plasma from 35 T2D patients and 35 age- and sex-
matched healthy controls. Cholesterol efflux to HDL was determined in vitro, normalized for HDL cholesterol, using 
cholesterol-loaded macrophages. Efflux capacity of plasma HDL was 10% lower in T2D patients than in healthy controls, 
in line with previous observations. This difference was much more pronounced for HDL from IF, where efflux capacity 
was reduced by 28% in T2D. Somewhat surprisingly, the efflux capacity of HDL from IF was lower than that of plasma 
HDL, by 15% and 32% in controls and T2D patients, respectively.
Conclusion—These data demonstrate that (1) HDL from IF has a lower cholesterol efflux capacity than plasma HDL 
and (2) the efflux capacity of HDL from IF is severely impaired in T2D when compared with controls. Because IF 
comprises the compartment where reverse cholesterol transport is initiated, the marked reduction in cholesterol efflux 
capacity of IF-HDL from T2D patients may play an important role for their increased risk to develop atherosclerosis. 
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efflux from peripheral cells is considered a crucial step.9 
Thus, measurements of this efflux capacity have shown to be 
independently related to the risk for cardiovascular events.10 
Accordingly, T2D patients generally have been demonstrated 
to display reduced cholesterol efflux capacity.11–14
As reverse cholesterol transport is initiated in the extra-
vascular compartment in peripheral tissues,9 evaluating efflux 
capacity of HDL from IF might be more relevant than study-
ing plasma HDL. Various aspects of HDL metabolism have 
previously been studied in IF (ie, peripheral lymph).15–17 
However, to the best of our knowledge, there are no reports on 
HDL-mediated cholesterol efflux using HDL from IF, neither 
in healthy subjects nor in T2D patients. Therefore, we mea-
sured in vitro cholesterol efflux capacity of HDL isolated from 
both IF and plasma obtained from a previous study of T2D 
patients and healthy controls.3
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Lipoprotein Sizes in Serum and IF From 
T2D Patients and Healthy Controls
LDL and HDL particle diameters, calculated from the fast 
performance liquid chromatography (FPLC) retention times, 
are shown in the Table (absolute retention times are given in 
Table I in the online-only Data Supplement and the FPLC pro-
files are given in Figure IA and IB in the online-only Data 
Supplement). Compared with controls, the calculated HDL 
particle diameters in T2D patients were reduced by 6.3% 
and 4.6% in serum and IF, respectively. When comparing 
sizes of HDL particles in IF with those in serum in the same 
study groups, we found that the HDL particle size in IF was 
increased by 4.4% in controls and by 6.4% in T2D patients 
(Table).
The LDL particle size in T2D patients was smaller than 
in controls, by 2.7% and 1.9% in serum and IF, respectively. 
LDL size did not differ between serum and IF, neither in T2D 
patients nor in controls (Table).
Lipid Composition of HDL in Serum and IF 
From T2D Patients and Healthy Controls
Phospholipid content of HDL from serum and IF was ana-
lyzed by FPLC (the FPLC profiles are shown in Figure IIC 
and IID in the online-only Data Supplement). T2D patients 
were found to have reduced levels of phospholipids in HDL 
from both serum and IF when compared with controls (Table 
II in the online-only Data Supplement). As described previ-
ously,3 triglyceride and unesterified cholesterol contents of 
HDL, together with esterified cholesterol content of HDL 
(calculated from total cholesterol and unesterified cholesterol) 
were determined and are shown in Table II in the online-only 
Data Supplement; the FPLC profiles for unesterified choles-
terol and triglycerides are given in Figures IC and ID and IIA 
and IIB. The percentage composition of HDL lipids in relation 
to total (Table) was calculated from the lipid data in Table II in 
the online-only Data Supplement. From these calculations, it 
was found that serum HDL from T2D patients had decreased 
content of unesterified cholesterol and increased triglyceride 
content compared with healthy controls, whereas for esteri-
fied cholesterol and phospholipids, there were no differences 
(Table). HDL from IF from T2D patients had a reduced con-
tent of esterified cholesterol and an increased content of phos-
pholipids. For unesterified cholesterol and triglycerides, there 
were no differences (Table). When comparing lipid composi-
tion in HDL from serum and IF, respectively, it was found that 
HDL from IF contained more esterified cholesterol, unesteri-
fied cholesterol, and triglycerides, but substantially less phos-
pholipids than did HDL from serum, in both T2D patients and 
healthy controls (Table).
HDL-Mediated Cholesterol Efflux 
Capacity in Plasma and IF in T2D 
Patients and Healthy Controls
Cholesterol efflux to HDL, normalized for HDL choles-
terol, was assayed using a standardized in vitro system 
based on THP-1–derived macrophage foam cells loaded 
with 3H-cholesterol.18 As expected, plasma HDL from T2D 
patients had a 10% lower efflux capacity when compared with 
healthy controls (Figure). The efflux capacity of IF-HDL was 
reduced by 28% in samples from T2D patients compared with 
those from controls (Figure). Comparing the efflux capaci-
ties of HDL from IF with those from plasma in controls and 
in T2D, respectively, it was found that efflux to HDL-IF was 
15% lower in healthy controls whereas the reduction in T2D 
was even more pronounced (32%; Figure).
Discussion
To the best of our knowledge, cholesterol efflux measure-
ments using HDL isolated from IF have not been reported 
previously. In our study, we could demonstrate that choles-
terol efflux to HDL of interstitial origin was clearly of lower 
magnitude than that to plasma HDL, in both healthy controls 
and T2D patients. Because the process of cholesterol loading 
of HDL particles is thought to mainly take place in periph-
eral tissues,16,17 the evaluation of cholesterol efflux capacity 
of HDL from IF may, therefore, be of higher physiological 
relevance than measurements of the efflux capacity of HDL 
from plasma.
We could confirm the results of previous reports by show-
ing a 10% reduction in plasma HDL cholesterol efflux in T2D 
patients in comparison with healthy subjects.11–14 However, not 
all studies have been able to detect differences between T2D 
patients and healthy controls,19,20 and 1 study has reported an 
increased efflux capacity in T2D patients.21 These incongru-
ent results might be related to not only the varying degree of 
severity of disease of the patients studied but also differences 
in the cell systems used in the efflux assays. It is important to 
Nonstandard Abbreviations and Acronyms
FPLC fast performance liquid chromatography
IF interstitial fluid
T2D type 2 diabetes mellitus
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note that the reduced capacity for cholesterol efflux that we 
observed for HDL from plasma of T2D patients was much 
more pronounced for HDL from IF.
A potential limitation of our study is the fact that some 
T2D patients were on statin and fibrate treatments, alone or in 
combination, a situation that might have improved cholesterol 
efflux.18,22,23 However, also in this case, the published literature 
is not consistent because unaltered21,23,24 or even decreased24 
efflux capacity has been observed. We did not see any signifi-
cant difference comparing T2D patients with or without lipid-
lowering therapy in this respect (Table III in the online-only 
Data Supplement). The fact that many patients had docu-
mented cardiovascular disease should also be noted.
Small HDL particles have been reported to be more effi-
cient to promote cholesterol efflux from cells.25,26 Our finding of 
reduced HDL particle size in IF and serum from T2D patients 
may at first appear somewhat puzzling although the observa-
tion of a reduced size of serum HDL in T2D is in agreement 
with previous work.27 It should be pointed out that the analysis 
of different subclasses of HDL is not possible using our tech-
nique. Increased glycation of HDL in T2D may contribute to 
the reduced cholesterol efflux28 although such a phenomenon 
has also not been found universally.21 From our calculated data 
on percentage composition of the different lipids in HDL, we 
show that the percentage of esterified cholesterol in serum 
HDL, the main component of the core of HDL, did not differ 
between healthy controls and T2D patients. For HDL from IF, 
the percentage of esterified cholesterol was reduced in T2D 
patients, which could contribute to the reduced HDL size.
Previous work has concluded that HDL from peripheral 
lymph carries more cholesterol than can be explained by 
transendothelial transfer of HDL from plasma,16 and that the 
infusion of apoAI/phosphatidylcholine discs increases the cho-
lesterol content of HDL in peripheral lymph.17 Those results 
support the hypothesis that HDL acquires cholesterol within 
peripheral tissues. From this reasoning, we expected that the 
cholesterol efflux capacity should be higher for HDL isolated 
from IF than from plasma. Instead, we found the opposite. The 
reduced cholesterol efflux capacity of HDL from IF compared 
with those from plasma was accompanied by increased HDL 
size, in both patients and controls. This relationship fits well 
with the previously reported association between small HDL 
and increased efflux capacity.25,26
Table.  LDL and HDL Sizes and Lipid Composition of HDL in Serum and IF From T2D Patients and Controls
Serum
P Value (Healthy Controls 
vs T2D Patients) IF
P Value (Healthy Controls 
vs T2D Patients) P Value (Serum vs IF)
Healthy controls
  LDL (nm) 21.11±0.34 … 21.07±0.40 … n.s.
  HDL (nm) 8.91±0.35 … 9.31±0.46 … <0.01
  CE in HDL (%) 28.3±4.2 … 41.5±5.0 … <0.0001
  FC in HDL (%) 10.3±2.2 … 17.9±2.8 … <0.0001
  TG in HDL (%) 4.9±2.3 … 8.5±2.8 … <0.0001
  PL in HDL (%) 56.5±4.6 … 32.1±4.6 … <0.0001
T2D patients
  LDL (nm) 20.53±0.45 <0.001 20.68±0.37 <0.001 n.s.
  HDL (nm) 8.35±0.40 <0.001 8.88±0.66 <0.001 <0.001
  CE in HDL (%) 27.3±7.1 n.s. 35.4±6.5 <0.001 <0.0001
  FC in HDL (%) 8.8±3.1 <0.01 16.8±4.3 n.s. <0.0001
  TG in HDL (%) 6.9±2.1 <0.0001 9.8±3.7 n.s. <0.001
  PL in HDL (%) 57.0±7.7 n.s. 38.0±4.4 <0.0001 <0.0001
Data are mean±SD. For percentage lipid composition, serum data were missing from 3 healthy controls and IF data from 1 healthy control. P values indicate the 
significance of difference from the same fluid in the control group or between serum and IF within the individual groups, as indicated (2-way ANOVA followed by 
Bonferroni multiple comparison test). CE indicates esterified cholesterol; FC, unesterified cholesterol; HDL, high-density lipoprotein; IF, interstitial fluid; LDL, low-density 
lipoprotein; PL, phospholipid; T2D, type 2 diabetes mellitus; and TG, triglyceride.
Figure. Cholesterol efflux capacity of high-density lipoprotein 
from plasma and interstitial fluid (IF) from type 2 diabetes mel-
litus (T2D) patients and healthy controls. Data are presented 
as mean±SD. Plasma was available from all subjects, whereas 
IF was available from 21 healthy controls and 24 T2D patients. 
**P<0.01, ***P<0.001 (2-way ANOVA followed by Bonferroni mul-
tiple comparison test).
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The phospholipid content of HDL is shown to be one of 
the major drivers of cholesterol efflux.29 The reduced cho-
lesterol efflux to IF-HDL may, therefore, at least in part, be 
explained by the substantially reduced phospholipid content 
in those particles compared with serum HDL. These results 
further support the importance of HDL-phospholipid for cho-
lesterol efflux capacity.
Interestingly, it has been shown in vitro that phospholipid 
hydrolysis by endothelial lipase contributes to transendothelial 
transport of HDL.30 This may very well explain the reduced 
level of HDL-phospholipid in IF compared with serum. This 
transendothelial movement of HDL also reduces HDL size.30 
In this study, we found increased HDL size in IF, which may 
be explained by increased percentage of esterified cholesterol. 
Although not completely comparable, our results showing 
larger HDL size in suction blister fluid are also in agreement 
with the reported increased abundance of large HDL particles 
in peripheral prenodal lymph.16 As HDL particles are pro-
posed to acquire cholesterol in IF before returning to plasma 
via the lymph, it is reasonable that HDL size is increased in 
lymph. HDL isolated from suction blister fluid may already 
have acquired saturating levels of cholesterol from peripheral 
cells, resulting in larger size and decreased detected efflux 
capacity.
Analyzing samples from the same patients and controls, 
we recently showed that T2D patients have unexpectedly 
reduced levels of apoB-containing lipoproteins in IF, possibly 
mirroring an increased uptake by, or adhesion to, interstitial 
constituents. In contrast, the IF:serum ratio for HDL was not 
influenced by T2D.3 The present demonstration of a signifi-
cantly lower cholesterol efflux to HDL from IF suggests that, 
in addition to an increased peripheral disposal of apoB-con-
taining lipoproteins, the capacity to remove deposited choles-
terol is reduced in T2D. Altogether, our results indicate that 
the interstitial compartment, which should reflect the meta-
bolic conditions in the arterial wall, may be an important loca-
tion for several disturbances of cholesterol metabolism that 
might explain the increased propensity for atherosclerosis in 
T2D.
In conclusion, the capacity to promote cholesterol efflux is 
considerably lower for HDL from IF than HDL from plasma, 
both in healthy controls and T2D patients. Moreover, in IF 
from T2D patients, the efflux capacity of HDL is strongly 
impaired when compared with that in healthy controls. 
Interventions directed at promoting HDL-mediated choles-
terol efflux in the IF compartment may be a successful new 
way to target the increased risk of atherosclerosis and cardio-
vascular disease in T2D.
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This study shows that cholesterol efflux to high-density lipoprotein from interstitial fluid is strongly suppressed in type 2 diabetes mellitus 
patients. This study analyzes cholesterol efflux in interstitial fluid, an important measurement because the first step in reverse cholesterol 
transport, namely loading of high-density lipoprotein with cholesterol, occurs in the interstitial compartment. The results contribute important 
knowledge to understand why type 2 diabetes mellitus patients are at increased risk of developing atherosclerosis.
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Supplementary Table I. Retention time for lipoproteins from serum and IF from T2D 
patients and healthy controls. 
 
Data are means±SD. P values indicate the significance of difference from the same fluid in 
the control group or between serum and IF within the individual groups, as indicated (Two-






P value  
(healthy 




P value  
(healthy 
control vs.  
T2D patients) 





     
     LDL 39.29±0.31  39.32±0.36  n.s. 
     HDL 50.42±0.32  50.06±0.42  <0.01 







     LDL 39.82±0.41 <0.001 39.68±0.34 <0.001 n.s. 
     HDL 50.93±0.37 <0.001 50.45±0.60  <0.001 <0.001 
2 
 
Supplementary Table II. Serum and IF apoAI, and lipid content of HDL from serum and 
IF, from T2D patients and controls. 
 
CE, esterified cholesterol; FC, unesterified cholesterol. HDL total cholesterol, FC, TG and 
apoAI data have been published previously (Apro et al. J Lipid Res. 2015 Aug;56(8):1633-9) 
and CE was calculated from total cholesterol and FC concentrations. Data are means±SD. P 
values indicate the significance of difference from the same fluid in the control group, as 
indicated (Two-way ANOVA followed by Bonferroni’s multiple comparison test). In serum, 
values for FC (and consequently CE) are missing from three healthy controls, and in IF from 
one healthy control. One value for serum apoAI in healthy controls is excluded because of 




Serum  P value  
(healthy 





P value  
(healthy 
control vs.  
T2D patients) 
P value  
(Serum vs. 
IF) 
Healthy controls      
HDL CE (mmol/L) 1.10±0.32  0.284±0.098  <0.0001 
HDL FC (mmol/L) 0.41±0.16  0.123±0.050  <0.0001 
HDL TG (mmol/L) 0.183±0.059  0.055±0.019  <0.0001 
  HDL PL (mmol/L)  2.24±0.57  0.210±0.041  <0.0001 
ApoAI (g/L) 0.83±0.14  0.188±0.055   
      
T2D patients      
HDL CE (mmol/L) 0.67±0.20 <0.0001 0.177±0.081 <0.0001 <0.0001 
HDL FC (mmol/L) 0.23±0.12 <0.0001 0.082±0.036 <0.001 <0.0001 
HDL TG (mmol/L) 0.167±0.048 n.s. 0.045±0.016 <0.01 <0.0001 
HDL PL (mmol/L) 1.47±0.57 <0.0001 0.177±0.040 <0.05 <0.0001 
ApoAI (g/L) 0.67±0.14 <0.001 0.124±0.035 <0.0001 <0.0001 
3 
 
Supplementary Table III. Cholesterol efflux to HDL from plasma and IF from T2D 
patients treated or not treated with statins and/or fibrates. 
 
Data are means±SD. For T2D patients not treated with statins and/or fibrates, plasma was 
available from 11 patients and IF was available from 7 patients. For T2D patients treated with 
statins and/or fibrates, plasma was available from 24 patients and IF was available from 17 
patients. P values indicate the significance of difference from the same fluid in the T2D group 
not treated with statins and/or fibrates or between plasma and IF within the individual groups, 
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P value  
(Not treated vs.  
treated with 
statins/fibrates) 
P value  
(Plasma 
vs. IF) 







      
Treated with 
statins/fibrates 




Supplementary Figure I. FPLC lipoprotein profiles for total (A-B) and unesterified (C-D) 
cholesterol in serum and IF from healthy controls and T2D patients. Data are presented 
as means (thick lines) ±SD (thin lines). The approximate elution profiles of the lipoprotein 
classes are indicated. The absorbance values for IF were divided by five to adjust for the 
higher sample volume analyzed compared with serum. Data for unesterified cholesterol in 











Supplementary Figure II. FPLC lipoprotein profiles for TG (A-B) and PL (C-D) in serum 
and IF from healthy controls and T2D patients. Data are presented as means (thick lines) 
±SD (thin lines). The approximate elution profiles of the lipoprotein classes are indicated. The 
absorbance values for IF were divided by ten to adjust for the higher sample volume 
analyzed compared with serum. 
 
 
Materials and Methods 
 
Subjects and study design 
Thirty-five T2D patients and thirty-five age- and gender-matched healthy controls were 
studied, as described previously.1 Written informed consent was obtained at inclusion. The 
study was approved by the regional ethics review board in Stockholm and conducted in 
accordance with the Declaration of Helsinki.  
 
Collection of IF, serum, and plasma 
Peripheral blood samples and suction blister fluid were collected after an over-night fast, as 
previously described.1  
 
Determination of lipoprotein size 
Lipoprotein cholesterol profiles were determined with FPLC, as described,1 and the retention 
times for the LDL and HDL peaks were used to calculate particle size. For this purpose, a 
linear regression equation was generated using the mean retention times for serum HDL and 
LDL in healthy controls (being 50.42 and 39.29 minutes, respectively), together with 
published particle sizes in healthy subjects (LDL 21.1 nm, and HDL 8.9 nm).2, 3  
 
Determination of lipoprotein lipid and apolipoprotein composition  
Total and unesterified cholesterol as well as TG were determined as described.1 PLs were 
determined in 2 µL of serum and 20 µL of IF, using reagents from WAKO Diagnostics, 
Richmond, VA. ELISA was used to analyze apoAI (Mabtech, Nacka strand, Sweden), as 
described.1  
 
Assessment of cholesterol efflux 
HDL was isolated from IF and plasma by ultracentrifugation (1.063<d<1.21 g/mL) using a 
Beckman optima TLX ultracentrifuge (Beckman Coulter, Pasadena, CA), followed by dialysis 
in GeBAflex tubes (Gene Bio-Application Ltd, Yavne, Israel). Cholesterol efflux to HDL was 
assayed in 48-well plates using THP-1 human monocytes (ATCC via LGC Promochem, 
Teddington, UK) differentiated into macrophages, essentially as described.4 Differentiated 
cells were loaded for 24 hours using RPMI 1640 medium supplemented with 50 μg/mL 
acetylated LDL and 1 μCi/mL 3H-cholesterol (Perkin Elmer, Boston, MA) followed by 
equilibration for 24 hours in RPMI 1640 medium containing 2% bovine serum albumin. Efflux 
was initiated by adding HDL at a final concentration of 1 mg/dL cholesterol. After 5 hours 
incubation at 37°C, the medium was collected and centrifuged to remove cellular debris. The 
cells were incubated for at least 30 minutes at room temperature with 0.1 mol/L NaOH. 
Radioactivity was determined both in medium and cells by liquid scintillation counting 
(Packard 1600CA Tri-Carb, Packard, Meriden, CT). Efflux per well is expressed as the 
percentage of counts released into the medium related to the total dose of radioactivity 
initially present (counts recovered within the medium added to the counts recovered from the 
cells). Values obtained from control cells without added HDL were subtracted to correct for 
unspecific efflux. Cholesterol efflux measurements were carried out in all respective samples 
at the same time to limit potential variation due to different assay conditions. All 
measurements were performed in duplicate. A standard curve with control HDL was present 
on each plate to allow correction for potential variations between plates. For efflux analysis, 
plasma was available from all subjects, while IF was available from 21 healthy controls and 
24 T2D patients.  
 
Statistical analysis 
Values are presented as mean±standard deviation (SD) and were log transformed prior to 
statistical analysis performed with two-way analysis of variance (ANOVA) followed by 
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